Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram

European Archives of Psychiatry and Clinical Neuroscience

Volumn 261, Issue 3, 2011, Pages 147-156

  Papakostas, George I ^a   Larsen, Klaus ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

Antidepressant; Anxious; Depression; Moderator; Predictor; Unipolar

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY; ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR DEPRESSION; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHINOPHARYNGITIS; SOMATIZATION; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CITALOPRAM; CLINICAL TRIALS AS TOPIC; DATABASES, BIBLIOGRAPHIC; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 79958730147     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-010-0149-3     Document Type: Article

References (38)

1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006) STAR*D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163(1):28-40
2. Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287(14):1840-1847 (Pubitemid 34303629)
3. Melander H, Salmonson T, Abadie E, van Zwieten-Boot B (2008) A regulatory Apologia-a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18(9):623-627
4. Papakostas GI, Fava M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19(1):34-40
5. Papakostas GI, Fava M (2008) Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci 10:439-451
6. Kraemer HC, Wilson GT, Fairburn CG, Agras WS (2002) Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 59(10):877-883
7. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF (1997) Major depressive subtypes and treatment response. Biol Psychiatry 42(7):568-576 (Pubitemid 27425475)
8. Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, Wohlreich MM (2007) The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a posthoc analysis of an open label outpatient study. Ann Clin Psychiatry 19(3):187-195 (Pubitemid 47345874)
9. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 165(3):342-351 (Pubitemid 351704490)
10. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH (2008) Selecting among secondstep antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 65(8):870-880
11. Howland RH, Wilson MG, Kornstein SG, Clayton AH, Trivedi MH, Wohlreich MM, Fava M (2008) Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry 20(4): 209-218
12. Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M (2008) Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res 161(1):116-120
13. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J, Group for the Study of Resistant Depression (2007) Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68(7):1062-1070 (Pubitemid 47340327)
14. Nelson JC, Delucchi K, Schneider LS (2009) Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis. Int J Geriatr Psychiatry 24(5): 539-544
15. Nelson JC (2010) Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety 27(1):12-18
16. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M (2008) Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 69(8): 1287-1292
17. Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241 (Pubitemid 32183606)
18. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007) Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62(11):1217-1227 (Pubitemid 350060895)
19. Hamilton MA (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
20. Burke WJ, Gergel I, Bose A (2002) Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336 (Pubitemid 34456361)
21. Rapaport MH, Bos, A, Zheng H (2004) Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 65:44-49. See also: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?-file-id=scsr/ SCSR-SCTMD-02-final.pdf
22. Bose A, Li D, Gandhi C (2008) Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 16:14-20
23. Forest Laboratories (2001) Flexible dose comparison of the safety and efficacy of escitalopram and fluoxetine in the treatment of major depressive disorder. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?- file-id=scsr/SCSR-SCT-MD-16-final.pdf. Accessed 21 June 2007
24. Ninan PT, Ventura D, Wang J (2003) Escitalopram is effective and well tolerated in the treatment of severe depression. Poster presented at the Congress of the American Psychiatric Association, May 17-22, San Francisco, CA. See also: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?- file-id=scsr/SCSR-SCT-MD-26-final.pdf
25. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I (2006) A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21:159-169 (Pubitemid 43740307)
26. Boulenger JP, Huusom AKT, Florea I, Bækdal T, Sarchiapone M (2006) A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 22:1331-1341 (Pubitemid 44085585)
27. Ventura D, Armstrong EP, Skrepnek GH, Erder MH (2007) Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 23:245-250 (Pubitemid 46333371)
28. Alexopoulos GS, Gordon J, Zhang D (2004) A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology 29(suppl):S87. See also: http://www. forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?-file-id=scsr/ SCSR-SCT-MD-27-final.pdf
29. Montgomery SA, Huusom AKT, Bothmer J (2004) A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50:57-64 (Pubitemid 38721171)
30. Bielski RJ, Ventura D, Chang C-C (2004) A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder. J Clin Psychiatry 65:1190-1196
31. Wade AG, Gembert K, Florea I (2007) A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 23:1605-1614 (Pubitemid 47122170)
32. Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C (2007) Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Invest 27:481-492 (Pubitemid 46919700)
33. Cleary P, Guy M (1977) Factor analysis of the Hamilton depression rating scale. Drugs Exp Clin Res 1:115-120
34. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389 (Pubitemid 9136500)
35. Papakostas GI, Petersen T, Hughes ME, Nierenberg AA, Alpert JE, Fava M (2004) Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res 126:287-290 (Pubitemid 38626189)
36. Kennedy SH, Andersen HF, Thase ME (2009) Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 25(1):161-175
37. Fava M, Alpert JE, Carmin CN et al (2004) Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 34(7): 1299-1308 (Pubitemid 39517160)
38. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM (2007) Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a noninferiority study. Curr Med Res Opin 23(2):401-416 (Pubitemid 46333388)